Browse Category

NASDAQ:REPL 21 October 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. This reversed a mid-year collapse – in July 2025 a disappointing FDA Complete Response Letter caused the stock to collapse ~73% in one day globenewswire.com. Over the past year the 52-week trading range is roughly $2.68 to $17.00 marketbeat.com, reflecting that roller-coaster.
21 October 2025
·
Follow on Google News
Add as preferred source Open in Google News
LIVE • LATEST MARKET MOVES

Live updates

  1. Expand Energy (EXE) Delivers 115% Five-Year Return, Trades at a Discount to Estimated Value
    Expand Energy (EXE) posted a 115.4% total return over five years but has fallen 9.0% over the past year. The stock is priced at a P/E of 7.7x, well below both the Oil and Gas industry average of 13.9x and Simply Wall St's estimated fair P/E of 15.2x. The $1.25b Twin Eagle acquisition could influence its valuation, but EXE is currently identified as undervalued across all 6 valuation metrics.
  2. Omnicell (OMCL) Shares Slide 9.9% After Cautious Q3 Forecast Offsets Q2 Beat
    Shares of Omnicell declined 9.9% following guidance for Q3 revenue of $304 million, which came in 2.9% below analyst expectations. The company had exceeded forecasts with Q2 revenue of $312.2 million and adjusted earnings per share of $0.94, but concerns arose due to the subdued outlook and an EPS guidance miss. So far this year, the stock has fallen 18.3% and remains 28.3% under its 52-week peak of $51.39.
  3. Garrett Motion (GTX) Gains After Deutsche Bank Upgrade, Q2 Outperformance
    Garrett Motion (NYSE: GTX) shares climbed 6.6% after Deutsche Bank upgraded the stock to Buy and raised its price target to $36. This followed stronger-than-expected Q2 results and a better full-year 2026 guidance, underlining strong performance and confidence in future earnings. GTX has advanced 74.9% so far this year, although it remains 16.1% below its 52-week high of $36.23, following earlier volatility.